A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors - Concepedia

Concepedia

Publication | Open Access

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

DOI Full Paper Access

43

Citations

34

References

2018

Year

Florence Atrafi, Harry J.M. Groen, Lauren A. Byers, Elena Garralda, Martijn P. Lolkema, Randeep Sangha, Santiago Viteri, Young Kwang Chae, D. Ross Camidge, Nashat Gabrail,

Clinical Cancer Research

Abstract

Veliparib (240 mg b.i.d. 14 days) plus carboplatin/etoposide can be safely combined. Phase II of this study is ongoing in first-line patients with ED SCLC.

References

	Year	Citations

Page 1